Strong quarter masked by one-time gains; core margins thin

Consolidated revenue +27.4% to ₹441.9 Cr; film segment ₹399.4 Cr (standalone film ₹347.7 Cr +22%)

Achieved 45.3% margin but on 24% lower volume and 32% lower revenue; driven by product mix not operational leverage

Ester Industries 85%, Ester Filmtech 83% – consolidated claim accurate

6,368 MT vs prior-year implied ~5,180 MT; 29% of 22,120 total = 6,415 MT, broadly consistent

Other income ~₹10 Cr (treasury, FD interest, forex gains); operating profit ~₹8.6 Cr ≈ 2% NPM. Reported margin inflated by one-off gains

Growth achieved but external sales pressured by internal demand reallocation; sequential decline withheld from disclosure

Prior: expected formal anti-dumping duties to create moat. Actual: benefiting from China 'anti-involution' policy and tighter trade flows (temporary, not structural)

Prior: targeting 20–25% revenue contribution in FY27. Actual: acknowledging flat-to-single-digit growth FY27 due to demand pressure on high-margin products; 20% CAGR deferred to next financial year

Prior: structural margin improvement via anti-dumping duties. Actual: margin lift from temporary supply-demand tightness, VAS mix (still nascent at 29%), and one-off other income

Mgmt confirmed in-house consumption is primary; external sales secondary and cyclical (currently pressured by internal reallocation)

Industry structure favorable for 6–8 quarters of sustainable earnings. Other income component exists; excluding that, ample opportunity for volume and profitability from supply-demand balance.

Driven by higher prices, better capacity utilization (films, polymers, rPET), specialty product mix leverage, and operational efficiency. We are steadily marching towards ₹2,000–2,200 Cr in 2–3 years.

Global prices improved due to restricted trade flows. Spreads Q1: ₹28–30 for 12-micron commodity film, VAS commands ₹25+ premium. Expect spreads sustained 6–8 quarters.

Up to 35% contribution by exit quarter (Q4), then targeting 50–60% in 2–3 years.

Temporary slowdown. External sales hit because internal demand for rPET in packaging films increased. Recovery expected in September, more visible in Oct–Dec quarter.

Large market, room for many players. Loop's technology differentiator: processes low-cost feedstock (blends, colors), competitor tech needs near-pure polyester. Maturity & economics favor us. Pre-commitments (Nike, athletic brand for 15k MT/yr) validate market.

Primary logic is in-house consumption. External sales are secondary. Measure of success is total value (internal + external). Producing much larger volumes than last year; expect >100% rated capacity by exit quarter.

VAP share growing but from small base. As VAP scales, percentage margins will moderate due to lower mid-margin profile, but absolute EBITDA/EBIT to grow due to operating leverage. Focus on absolute top-line and EBIT growth, not percentages.

₹100 Cr debt repayment this year. ELITe is separate JV; additional debt raised in JV, not consolidated (50–50 structure). No major capex for FY27 in standalone/polymer.

Investment income from ₹200+ Cr cash, favorable forex gains (vs negative last quarter). This is one-time gain; not expected on sustainable basis.

We are looking at sustainable growth in revenues and profitability. At this point, we would hold back from giving very firm guidance on specific revenue and EBITDA numbers.

Treasury ₹3 Cr, FD interest ₹3.5 Cr, forex gain ₹1 Cr, other balance. This was inflated by positive equity/forex vs prior quarter negative. One-time gain; sustainable level lower.

Gross debt ₹720 Cr → ₹620 Cr (₹100 Cr repayment). Cash ₹235 Cr, but ₹140 Cr earmarked for JV investment. Sustainable liquidity ~₹100 Cr.

~1.35 M tons total capacity, ~85% industry utilization. Capacity additions 2 lines in past 1.5 years, but demand growth outpaced. Expect 2–3 more lines in next 1.5–2 years.

20% CAGR is over 3–5 years, not FY27 specifically. FY27: flat or single-digit growth due to demand pressure on high-margin product. Pipeline matures in H2; recovery expected in next financial year.

Long-term contracts with PTA/MEG suppliers; no production shortages in Q1. New GAIL capacity starts end-2026; already in discussion. IOC takes longer, RIL further. MEG: no new capacity, existing suppliers cover needs.

Enforcement still lax, but leading brands proactively switching to BOPET (from other substrates) and rPET-based films for regulatory readiness. Brands switching rapidly (not gradually) despite loose enforcement; this is the real pull for rPET demand.

28k ton rated capacity. Running at very high throughput already; expect to exceed 100% capacity by exit quarter (Q4 FY27). Not fully visible in financials due to internal consumption.

Filed patents on new products this year. Invention is way of life; challenge is long gestation period. Continue heavy R&D investment; many trade secrets not patented to protect from competitors.

Capture margins which would be paid to external supplier. Also usually cheaper than virgin raw material. We would like to avoid answering specific numbers (competitive sensitivity).

Similar, holding. Seeing resilience in commodity film spreads; no immediate compression expected.

Q2 capacity utilization looking better than Q1.

Rating review in progress; expect completion by end of this month. Ownership (Singhania's transfer to son) and management succession are separate; professionally managed, internal family matter.

No FY27 numeric guidance given. Target driven by higher prices, capacity utilization ramp (films, Specialty, rPET), specialty mix, operational efficiency

No specific margin target given. Acknowledged forex gains are one-time. Core operating margin ~2% ex-other income

Sustenance & maintenance capex only. ELITe expects ₹140 Cr from JV debt + equity (not consolidated)

Core film margins thin (2–2.5% ex-other income). Spreads ₹28–30 for commodity BOPET; mgmt expects 6–8 quarters sustainability but downside sharp if trade flows open, global capacity adds, or demand softens

₹10 Cr other income (forex ₹1 Cr, treasury ₹3 Cr, FD ₹3.5 Cr) represents 53% of reported PAT. Forex was negative in prior quarter; gains are cyclical. If forex reverses or MF valuations drop, reported PAT falls 50%+

Specialty volumes down 24% YoY to 725 MT; revenue -32% to ₹32.7 Cr. Mgmt cites demand pressure on high-margin products; recovery expected H2 FY27 but not guaranteed. If pipeline matures slower, FY27 revenue could shrink further; FY28 growth then at risk

28k MT rPET capacity; majority consumed internally (mixed into BOPET films), external sales are leftover. Sequential external decline (not disclosed) suggests internal demand drives utilization, not market pull. External profitability and scaling potential unclear

ELITe (50–50 Loop Industries JV) targets CY 2028 startup. Technology: chemical recycling of textile waste. Competitive risk: other players already operational; Loop's tech maturity (10+ years) is differentiator, but scaling unproven. Pre-commitments (Nike, brand LOI for 15k MT/year) de-risk demand but don't guarantee margin or cost assumptions

Gross debt ₹722 Cr; cash ₹236 Cr. Net debt ₹486 Cr. Debt repayment ₹100 Cr planned this year, but ₹140 Cr earmarked for ELITe equity contribution reduces liquid headroom to ~₹100 Cr. If earnings disappoint or capex overruns, leverage could spike